Analysis of cancer antigen expression in colorectal cancer patients' tissues
2015
Mount Sinai Roosevelt Hospital Center, New York, USA
Although surgery remains the main means of treating colorectal cancer patients, 40% of patients develop metastatic disease after surgery which prompts the need for new anti-cancer agents. IGF2BP3 (IMP3) is an mRNA binding protein present only in testis at adult age with increased expression in cancer patients. In the present study, the researchers wanted to determine if IGF2BP3 had potential as a vaccine target. Data were collected prospectively from CRC patients in an IRB-approved tissue and data bank. Patients' tissues were analyzed quantitatively for expression levels of IGF2BP3 in tumors and testis. Protein expression was assessed by immunocytochemistry. IGF2BP3 mRNA was overexpressed in 43% of the tumors whereas the protein was noted in 50% of samples. No correlation was seen between mRNA expression and disease severity. This protein represents a potential vaccine target, however, further research is needed.
Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target
Richard L. Whelan
Added on: 09-18-2021
[1] https://www.oncoscience.us/article/174/text/[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
